Before revision: As of 2016, the only site approved to manufacture the treatment was MolMed.Ben Adams for FierceBiotech 4 April 2016 Strimvelis to be the start of a whole new gene therapy platform for GSK and partners In
After revision: 2016, Strimvelis obtained Marketing Authorization in Europe while under GSK holding. the only site approved to manufacture the treatment was MolMed.Ben Adams for FierceBiotech 4 April 2016 Strimvelis to be the start of a whole new gene therapy platform for GSK and partners In